Affordable Access

deepdyve-link
Publisher Website

Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.

Authors
  • Pernas, Berta1
  • Grandal, Marta1
  • Tabernilla, Andrés1
  • Cid, Purificación2
  • Pértega, Sonia3
  • Castro-Iglesias, Ángeles1
  • Mena, Álvaro1
  • Margusino, Luis2
  • Pedreira, José D1
  • Poveda, Eva4
  • 1 Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain. , (Spain)
  • 2 Service of Pharmacy, Complejo Hospitalario Universitario de A Coruña, SERGAS, A Coruña, Spain. , (Spain)
  • 3 Clinical Epidemiology and Biostatistics Unit, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña, SERGAS, A Coruña, Spain. , (Spain)
  • 4 Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain. [email protected] , (Spain)
Type
Published Article
Journal
Journal of Medical Virology
Publisher
Wiley (John Wiley & Sons)
Publication Date
Dec 01, 2016
Volume
88
Issue
12
Pages
2125–2131
Identifiers
DOI: 10.1002/jmv.24585
PMID: 27218208
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period 2007-2015). The 43.2% had a CD4 nadir ≤100 cells/mm3 , 64.1% were treatment-experienced, and 36.5% had failed to >3 lines of antiretroviral therapy. Nonetheless, the rate of virological suppression (HIV-RNA <50 copies/ml) in naïve patients was 63%, 66.7%, and 63.6% at 48, 96, and 144 weeks, respectively. The rate of virological suppression in treatment-experienced patients was 62.7%, 78.7%, and 79.1% at 48, 96, and 144 weeks, respectively. No differences were observed according to the immunovirological status neither dosage of DRV/r. Most of them (82.6%) maintained DRV/r treatment. Causes for DRV/r discontinuation were mainly gastrointestinal and cutaneous adverse events (10.5%), switch to simplification treatment strategies (3.5%) and virological failure (1.7%). These findings demonstrate the prolonged efficacy and tolerability of DRV/r even in multi-treated HIV+ patients with an unfavorable immunovirological status. J. Med. Virol. 88:2125-2131, 2016. © 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times